cyprotex
the ADME Tox specialists
welcome to cyprotex

Investor News

August 18, 2010 - Director dealings

Cyprotex PLC ("Cyprotex" or the "Company")

Macclesfield, UK - Cyprotex PLC (LSE: CRX), a Contract Research Organisation (CRO) specialising in the preclinical ADME assessment of drug candidates, was informed on 17 August 2010 that certain directors acquired ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") on 17 August 2010. Details of the dealings are set out below:

Name

Title

 Price 

Shares acquired

Total interest

following dealing

% of total issued share capital

Steve Harris

Chairman

3.50

714,286

1,514,286

0.68

Anthony Baxter

CEO

3.50

228,571

1,069,971

0.48

John Dootson

CFO

3.50

550,000

550,000

0.25

Katya Tsaioun

CSO

3.50

1,828,571

24,193,720

10.82

Douglas Bates

CMO

3.50

5,485,715

27,850,862

12.45

 

For further information please contact:

Cyprotex PLC

Tel: +44 1625 505 10

Dr. Anthony Baxter, Chief Executive Officer

 

a.baxter@cyprotex.com

 

www.cyprotex.com

 

   

Singer Capital Markets Ltd

Tel: +44 203 205 7500

Shaun Dobson

 

Claes Spång

 

   

Financial Dynamics

Tel: +44 207 831 3113

Ben Brewerton

 

Ben Atwell

 

Mo Noonan

 

view all the latest news +
2013 archive +
2012 archive +
2011 archive +
2010 archive +
2009 archive +
2008 archive +
2007 archive +
2006 archive +
2005 archive +
2004 archive +
2003 archive +
2002 archive +
contact

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100

contact
careerscontactlegalprivacy
This website was last updated
on 16th April 2014
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.